Why Bluebird Bio's Stock Dived by Over 11% This Week

·2 min read

Despite its Friday lurch downwards, the stock market generally had a good week. Not every company on the exchange did well, however, and that list includes Bluebird Bio (NASDAQ: BLUE). The gene-editing specialist's shares fell more than 11% earthward, according to S&P Global Market Intelligence, as some pundits got more bearish after the company won regulatory approval for a new drug.